Significant publications on infectious diseases pharmacotherapy in 2008

American Journal of Health-System Pharmacy

Volumn 66, Issue 19, 2009, Pages 1726-1734

  Kuper, Kristi M ^a   Hirsch, Elizabeth B ^b,c   Tam, Vincent H ^b  

^a Cardinal Health ^*  (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c St Luke's Episcopal Hospital   (United States)

Author keywords

Antiinfective agents; Communicable diseases; Publications

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; COLISTIN; DIDANOSINE; EMTRICITABINE; FLUCONAZOLE; LAMIVUDINE; LINEZOLID; MEROPENEM; METRONIDAZOLE; OMEPRAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POLYMYXIN B; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VANCOMYCIN; VORICONAZOLE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ASPERGILLOSIS; CANDIDIASIS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; MEDICAL LITERATURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PUBLICATION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; HIV INFECTIONS; HUMANS;

EID: 70349755804     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090099     Document Type: Review

References (53)

1. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008; 149:391-398
2. Nobre V, Harbath S, Graf JD et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008; 177:498-505.
3. Yokoe DS, Mermel LA, Anderson DJ et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29(suppl 1):S12-21
4. Alexander BD, Perfect JR, Daly JS et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation. 2008; 86:791-796
5. Muñoz-Almagro C, Jordan I, Gene A et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008; 46:174-182
6. Noel GJ, Bush K, Bagchi P et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008; 46:647-655 (Pubitemid 351321545)
7. Mauldin PD, Salgado CD, Durkalski VL et al. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers. Ann Pharmacother. 2008; 42:317-326
8. Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2008; 29:671-674
9. Goff DA, Mangino JE. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J Infect. 2008; 57:123-127
10. Jackson ML, Nelson JC, Weiss NS et al. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet. 2008; 372:398-405.
11. Labelle AJ, Micek ST, Roubinian N et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008; 36:2967-2972
12. Dayan GH, Quinlisk MP, Parker AA et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008; 358:1580-9.
13. Garey KW, Lai D, Dao-Tran TK et al. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008; 52:446-451 (Pubitemid 351170812)
14. Katz DE, Lindfield KC, Steenbergen JN et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008; 62:1455-1464
15. Lisboa T, Diaz E, Sa-Borges M et al. The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest. 2008; 134:1208-1216
16. Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008; 46:1683-1693
17. Dantas G, Sommer MO, Oluwasegun RD et al. Bacteria subsisting on antibiotics. Science. 2008; 320:100-103
18. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36:309-332 [Erratum, Am J Infect Control. 2008; 36:655.] (Pubitemid 351763841)
19. Pertel PE, Bernardo P, Fogarty C et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008; 46:1142-1151 (Pubitemid 351589895)
20. Swanson JM, Wood GC, Croce MA et al. Utility of preliminary bronchoalveolar lavage results in suspected ventilator-associated pneumonia. J Trauma. 2008; 65:1271-1277
21. Hamza O, Matee M, Bruggermann R et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized double-blind, double-dummy trial. Clin Infect Dis. 2008; 47:1270-1276
22. Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008; 22:1389-1397
23. Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008; 47:123-130 (Pubitemid 351920599)
24. Molina J, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008; 372:646-655
25. Kumwenda NI, Hoover DR, Mofenson LM et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008; 359:119-129
26. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008; 65:65-70.
27. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet. 2008; 372:1881-1893
28. Fätkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008; 359:1442-1455
29. Nijland HM, L'homme RF, Rongen GA et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008; 22:931-935
30. Kuller LH, Tracy R, Belloso W et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5:e203.
31. Celum C, Wald A, Hughes J et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomized, double-blind, placebo-controlled trial. Lancet. 2008; 371:2109-2119 (Pubitemid 351902179)
32. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008; 359:1932-1940
33. DuPont HL, Garey K, Caeiro JP et al. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis. 2008; 21:500-507
34. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45:302-307
35. Louie T, Gerdsom M, Grimard D et al. Results of a phase III trial comparing tolevamer, vancomycin, and metronidazole in patients with Clostridium difficile associated diarrhea (CDI). Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL;2007 Sep.
36. Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for mortality among critically ill patients. Chest. 1999; 115:462-474 (Pubitemid 29083057)
37. Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007; 35:1888-1895 (Pubitemid 47220363)
38. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S16. Wayne, PA: Clinical Laboratory Standards Institute; 2006.
39. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med. 2006; 166:2138-2144
40. Maclayton DO, Suda KJ, Coval KA et al. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/L and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006; 28:1208-1216
41. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42:2398-2402 (Pubitemid 38747480)
42. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004; 38:1700-1705 (Pubitemid 38781661)
43. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother. 2008; 52:4528. Letter.
44. Rybak M, Lomaestro B, Rotschafer J et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82-98. [Erratum, Am J Health-Syst Pharm. 2009; 66:887.]
45. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416. (Pubitemid 40227463)
46. Dodds Ashley ES, Lewis R, Lewis JS et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006; 43(suppl 1):S28-39.
47. Lewis RE. What is the "therapeutic range" for voriconazole? Clin Infect Dis. 2008; 46:212-214
48. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39:309-17. (Pubitemid 39050477)
49. Glasmacher A, Pretice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with hematological malignancies. J Antimicrob Chemother. 2005; 56(suppl 1):i23-32. (Pubitemid 41236087)
50. Shorr AF, Chung K, Jackson WL et al. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005; 33:1928-1935 (Pubitemid 41306511)
51. Moise-Broder PA, Sakoulas G, Forrest A et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007; 51:2582-2586 (Pubitemid 47047340)
52. Lodise TP Jr, Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother. 2004; 48:4718-4724 (Pubitemid 39577677)
53. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356:1723-1735 (Pubitemid 46658704)